Ventricular Assist Devices (VAD)

This channel includes news and new technology innovations for ventricular assist devices (VAD). VADs are a type of mechanical hemodynamic support device that helps increase blood flow in people who have ventricles that are not work properly due to heart failure, cardiogenic shock, cardiomyopathy or myocardial infarction. Most often these devices support the left ventricle, so they are often referred to as left ventricular assist devices (LVAD). VADS come in two types, surgically implanted, usually as a bridge to heart transplant, and percutanenous catheter-based pumps used for temporary hemodynamic support. Examples of temporary percutaneous pumps include the Impella and TandemHeart devices.

 

The Abiomed Impella RP had higher than expected mortality in its post approval study, much higher than in its pre-market approval study. The vendor and the FDA believe this might be due to poor patient selection and implanting the device too late to aid the patient.
Feature | Hemodynamic Support Devices | Dave Fornell, Editor

The U.S. Food and Drug Administration (FDA) sent a letter to cardiologists this week to explain its evaluation of high ...

Home February 05, 2019
Home
Sponsored Content | Videos

Mark Anderson, M.D., FACS, vice chair of cardiac surgery services and cardiothoracic surgeon at Hackensack University ...

Home January 10, 2019
Home
Sponsored Content | Videos | Hemodynamic Support Devices

Michael Amponsah, M.D., FACC, an interventional cardiologist at Mohawk Valley Health System, shares a case of Impella CP ...

Home December 13, 2018
Home
News | Cardiovascular Surgery

December 11, 2018 — The scientific journal Nature recently published an article from Munich University Hospital which ...

Home December 11, 2018
Home
Sponsored Content | Videos | Cath Lab

Navin Kapur, M.D., discusses the results of the FDA STEMI Door-to-Unloading (DTU) safety and feasibility randomized ...

Home November 15, 2018
Home
A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC 2018. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at ACC earlier this year.
Feature | Heart Failure

October 19, 2018 — Abbott announced today that the HeartMate 3 Left Ventricular Assist Device (LVAD) has received U.S ...

Home October 19, 2018
Home
Videos | Hemodynamic Support Devices

Nevin Kapur, M.D., FAHA, FACC, FSCAI, executive director, Cardiovascular Center for Research and Innovation, Tufts ...

Home October 01, 2018
Home
News | Hemodynamic Support Devices

September 19, 2018 — Abiomed Inc. announces its initiatives at the 30th Transcatheter Cardiovascular Therapeutics (TCT) ...

Home September 20, 2018
Home
Sponsored Content | Videos | Cath Lab

William O’Neill, M.D., outlines his recent clinical publication of AMICS patients from the Impella Quality (IQ) database ...

Home September 19, 2018
Home
Videos | Hemodynamic Support Devices

Behnam Tehrani, M.D., FSCAI, director of the cardiac cath lab, INOVA Heart and Vascular Institute, Fairfax, Va ...

Home August 31, 2018
Home
Technology | Ventricular Assist Devices (VAD)

July 17, 2018 — Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive ...

Home July 17, 2018
Home
News | Ventricular Assist Devices (VAD)

July 11, 2018 — French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave ...

Home July 11, 2018
Home
Two versions of the Abiomed Impella percutaneous ventricular assist device being shown at ACC 2018. Impella is the only device currently cleared by the FDA for use in cardiogenic shock.
Feature | Hemodynamic Support Devices | Emmanouil S. Brilakis, M.D., Ph.D., FSCAI and Srihari S. Naidu, M.D., FSCAI
Cardiogenic shock (CS) is a low-cardiac-output state resulting in life-threatening end-organ hypoperfusion and hypoxia ...
Home July 08, 2018
Home
William O'Neill, M.D., unveils the Detroit Cardiogenic Shock Initiative at Henry Ford Hospital. The program uses new protocols to reduce cardiogenic shock mortality by 50 percent by using early hemodyanmic support.
Feature | Hemodynamic Support Devices | Dave Fornell, Editor

About 50 percent of patients in cardiogenic shock do not survive, and account for about 90,000 heart attack patients a ...

Home June 22, 2018
Home
Subscribe Now